Michel Perron

Michel Perron's work experience includes a recent role as the Executive Director of Discovery Biology at Assembly Biosciences, Inc., starting in February 2022. Prior to that, they held the position of Senior Director of Discovery Biology at the same company, from January 2021 to February 2022.

From November 2018 to January 2021, Perron worked as the Director and Head of Virology at The Janssen Pharmaceutical Companies of Johnson & Johnson.

Before that, from February 2015 to November 2018, they served as a Senior Research Scientist at Gilead Sciences, where they contributed to the discovery and development of GS-5734 for the treatment of Ebola. Perron also held the role of Research Scientist II at Gilead Sciences from January 2011 to February 2015, where they led a cross-functional team in a project focused on discovering and developing inhibitors for the treatment of respiratory syncytial virus (RSV). Additionally, they worked as a Research Scientist I at Gilead Sciences from July 2008 to December 2010, where they played a key role in the RSV biology core team and developed assays to study the mechanism of action of RSV inhibitors.

Earlier in their career, Perron served as a Senior Research Assistant at Henry Ford Health System from January 2001 to June 2003, where they conducted experiments to understand the mechanism of the serine protease inhibitor, Plasminogen Activator Inhibitor-1 (PAI-1). Michel also worked as a Research Assistant at Henry Ford Health System from January 1999 to December 2001, conducting molecular cloning and mutagenesis experiments related to PAI-1.

Michel Perron pursued their education with a strong focus on the sciences. From 1994 to 2001, they attended the University of Michigan-Dearborn, where they obtained a Bachelor of Science degree in Biochemistry and Microbiology. Following this, they continued their academic journey at Harvard Medical School from 2003 to 2007, earning a Ph.D. degree in Virology.